Loading...
Loading...
In a report published Wednesday, Morgan Stanley reiterated its Equal-Weight rating on Medicis Pharmaceutical Corp.
MRX, and raised its price target from $35.00 to $44.00.
Morgan Stanley noted, “We are lowering our 2013E EPS by 18% and trimming long- term (2014E-2020E) EPS by 13% on management's disappointing Sep. 17 proxy projections. Separately, we are raising our price target from $35 to reflect Valeant's $44/share bid.”
Medicis Pharmaceutical Corp. closed on Tuesday at $43.25.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in